Основная статистика
| CIK | 1448431 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to OptimizeRx Corporation
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 19, 2025 |
Exhibit 10.1 August 18, 2025 Brendan Merrell Dear Brendan, On behalf of OptimizeRx Corporation (the “Company”), we are excited to make this amended and restated employment offer to you for the full-time, exempt position of Chief Operating Officer (this “2025 Amended and Restated Merrell Employment Agreement”), effective as of August 18, 2025 (the “Effective Date”). For purposes of determining empl |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 15, 2025 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 19, 2025 |
OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth Exhibit 99.1 OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth WALTHAM, MA – August 19, 2025 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancemen |
|
| August 8, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 o Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| August 8, 2025 |
Fourth Amended and Restated Bylaws FOURTH AMENDED AND RESTATED BYLAWS OF OPTIMIZERX CORPORATION (A NEVADA CORPORATION) ARTICLE I OFFICES Section 1. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 7, 2025 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 7, 2025 |
OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance -Q2 revenue of $29. |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 20, 2025 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 24, 2025 |
OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors Exhibit 99.1 OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors WALTHAM, MA – June 24, 2025 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company’ |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| May 13, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 o Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| May 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2025 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 12, 2025 |
OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance -Q1 revenue of $21. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| April 18, 2025 |
OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment Exhibit 99.1 OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment WALTHAM, MA – April 18, 2025 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that, as part of OptimizeRx’s ongoing process to refresh a |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 18, 2025 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 3, 2025 |
VIA EDGAR April 3, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 28, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) OptimizeRx Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Common Stock, $0. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
Exhibit 4.1 OPTIMIZERX CORPORATION Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities. 5 Section 2.02 Form of Securities and Trustee’s Certificate. 8 Section 2.03 Denomina |
|
| March 20, 2025 |
Amendment No. 2 to Financing Agreement, dated September 26, 2024. Exhibit 10.21 Execution Version AMENDMENT NO. 2 TO FINANCING AGREEMENT AMENDMENT NO. 2 TO FINANCING AGREEMENT, dated as of September 30, 2024 (this “Amendment”), to the Financing Agreement, dated as of October 11, 2023 (as amended, restated, supplemented or otherwise modified from time to time, including by that certain Joinder Agreement, dated as of October 24, 2023, by and among the Lead Borrowe |
|
| March 20, 2025 |
Amendment No. 3 to Financing Agreement, dated February 5, 2025. Exhibit 10.22 Execution Version AMENDMENT NO. 3 TO FINANCING AGREEMENT AMENDMENT NO. 3 TO FINANCING AGREEMENT, dated as of February 5, 2025 (this “Amendment”), to the Financing Agreement, dated as of October 11, 2023 (as amended, restated, supplemented or otherwise modified from time to time, including by that certain Joinder Agreement, dated as of October 24, 2023, by and among the Lead Borrower |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38543 OptimizeRx Corporation (Exact name of re |
|
| March 20, 2025 |
OptimizeRx Corporation Insider Trading Policy Exhibit 19.1 OPTIMIZERX CORPORATION INSIDER TRADING POLICY This Insider Trading Policy (“Policy”) provides the standards of OptimizeRx Corporation (“OptimizeRx” or the “Company”) with respect to transactions in securities of the Company and the handling of confidential information about OptimizeRx and the companies with which OptimizeRx does business. The federal securities laws prohibit insider t |
|
| March 20, 2025 |
Exhibit 21.1 OptimizeRx Corporation List of Subsidiaries ● Healthy Offers, Inc. (d/b/a Medicx Health), a Nevada corporation ● CareSpeak Communications, d.o.o., a controlled foreign corporation incorporated in Croatia |
|
| March 20, 2025 |
Amended OptimizeRx Corporation Executive Severance Plan, dated March 7, 2025. Exhibit 10.19 AMENDED OPTIMIZERX CORPORATION EXECUTIVE SEVERANCE PLAN* Plan Document/Summary Plan Description OptimizeRx Corporation (the “Company”) has adopted this OptimizeRx Corporation Executive Severance Plan (the “Plan”) for the benefit of certain employees of the Company and its subsidiaries (hereinafter referred to as the “Company Group”), on the terms and conditions hereinafter stated, ef |
|
| March 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 12, 2025 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 12, 2025 |
OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results - Q4 revenue of $32.3 million, increasing 14% year-over-year - Q4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68% - Company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023 Waltham, MA. – March 12, 2025 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a l |
|
| March 11, 2025 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material Under Rule 14a-12 OptimizeRx Corporation (Name of Registrant as Specified in Its Charter) Whetstone Capital Advisors, LLC Whetstone Capital, LP Digital Economy Fund, LP David Atterbury Andrew Carlson John Fein (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (check the appropriate box): ☒ No fee required. |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 10, 2025 |
Exhibit 10.1 March 7, 2025 Stephen Silvestro XXXX XXXX Dear Steve, On behalf of OptimizeRx Corporation (the “Company”), we are excited to make this amended and restated employment offer to you for the full-time, exempt position of Chief Executive Officer (this “2025 Amended and Restated Employment Agreement”), effective as of March 10, 2025 (the “Effective Date”). For purposes of determining emplo |
|
| March 10, 2025 |
Exhibit 99.1 OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team WALTHAM, MA – March 10, 2025 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and enga |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 10, 2025 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 13, 2025 |
EX-99 3 d11514320ex99-b.htm Exhibit B CONTROL PERSON IDENTIFICATION Samjo Management, LLC is the relevant entity for which Andrew N. Wiener may be considered a control person. |
|
| February 13, 2025 |
EX-99 2 d11514320ex99-a.htm Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No. 1 dated February 13, 2025 relating to the Common Stock, par value $0.001, of OptimizeRx Corporation shall be filed on behalf of the undersigned. SAMJO MANAGEMENT, LLC By: /s/ Andrew N. Wiener Name: Andrew N. Wiener Title: Managing Member ANDREW N. WIENER By: /s/ Andrew N. Wiener |
|
| January 10, 2025 |
Exhibit 10.1 December 19, 2024 William Febbo XXX XXX XXX RE: Separation Agreement and Release of Claims; Advisory Terms & Conditions Dear Will, As discussed, OptimizeRx Corporation (the “Company”) Board of Directors and you have reached the difficult decision to mutually terminate your employment. The purpose of this letter agreement (this “Agreement”) is to establish an amicable arrangement for e |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 3, 2025 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 8, 2025 |
Exhibit A JOINT FILING AGREEMENT The Undersigned agree that the statement on Schedule 13G with respect to the common stock of OptimizeRx Corporation dated as of January 8, 2025, is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2024 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| December 23, 2024 |
Exhibit 99.1 OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO WALTHAM, Mass. – December 23, 2024 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that William J. Febbo, Chief Exe |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| November 14, 2024 |
OPRX / OptimizeRx Corporation / Divisadero Street Capital Management, LP Passive Investment SC 13G/A 1 d1152816913g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OptimizeRx Corporation (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 68401U204 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| November 13, 2024 |
Exhibit 99.1 OptimizeRx Reports Third Quarter 2024 Financial Results - Q3 revenue of $21.3 million, increasing 30% year-over-year - Q3 gross profit increased 37% year-over-year to $13.4 million with a gross margin of 63% - Won 5 DAAP deals during Q3 WALTHAM, Mass. – November 13, 2024 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping li |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2024 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| November 13, 2024 |
OPRX / OptimizeRx Corporation / Samjo Management, LLC Passive Investment SC 13G 1 d1151432013g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* OptimizeRx Corporation (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 68401U204 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2024 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 8, 2024 |
Exhibit 99.1 OptimizeRx Reports Second Quarter 2024 Financial Results - Q2 revenue of $18.8 million, increasing 36% year-over-year - Q2 gross profit increased 50% year-over-year to $11.7 million with a gross margin of 62% - Won 8 DAAP deals during Q2 WALTHAM, Mass. – August 8, 2024 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping li |
|
| July 23, 2024 |
As filed with the Securities and Exchange Commission on July 23, 2024 As filed with the Securities and Exchange Commission on July 23, 2024 Commission File No. |
|
| June 18, 2024 |
As filed with the Securities and Exchange Commission on June 18, 2024 As filed with the Securities and Exchange Commission on June 18, 2024 Commission File No. |
|
| June 18, 2024 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) OptimizeRx Corporation (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.001 |
|
| June 10, 2024 |
SC 13G/A 1 oprx-sc13ga061024.htm AMENDMENT TO FORM SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment) OptimizeRx Corporation (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 68401U204 (CUSIP Number) May 31, 2024 (Date of Event Which Requires Filing of this Statement) Check |
|
| June 7, 2024 |
Exhibit 10.1 AMENDMENT NO.1 TO THE OPTIMIZERX CORPORATION 2021 EQUITY INCENTIVE PLAN This Amendment No. 1 (this “Amendment No. 1”) to the OptimizeRx Corporation 2021 Equity Incentive Plan (the “2021 Equity Plan”), is hereby adopted as of April 25, 2024, by the Board of Directors (the “Board”) of OptimizeRx Corporation (the “Company”). All capitalized terms used in this Amendment No. 1 not otherwis |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 5, 2024 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| May 14, 2024 |
Exhibit 99.1 OptimizeRx Reports First Quarter 2024 Financial Results - Q1 revenue of $19.7 million, increasing 51% year-over-year - Q1 gross profit increased 64% year-over-year to $12.2 million with a gross margin of 62% - Won 9 DAAP deals during Q1 WALTHAM, Mass. – May 14, 2024 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life |
|
| May 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 14, 2024 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 26, 2024 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 29, 2024 |
Exhibit 99.1 OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET 1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million First quarter revenue and adjusted EBITDA to come in ahead of consensus DAAP adoption and cross selling activities are tracking ahead of internal expectations WALTHAM, Mass. – Ap |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| April 18, 2024 |
OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial Results - Q4 revenue of $28.4 million, increasing 44% year-over-year - Q4 gross profit increased 43% year-over-year to $17.8 million with gross margins coming in at 63% for both periods - Acquired Healthy Offers, Inc. (dba Medicx Health), a leading healthcare consumer-focused omnichannel marketing and analytics comp |
|
| April 18, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 16, 2024 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 15, 2024 |
OptimizeRx Corporation Insider Trading Policy Exhibit 19.1 OPTIMIZERX CORPORATION Insider Trading Policy This Insider Trading Policy (“Policy”) provides the standards of OptimizeRx Corporation (“OptimizeRx” or the “Company”) with respect to transactions in securities of the Company and the handling of confidential information about OptimizeRx and the companies with which OptimizeRx does business. The federal securities laws prohibit insider t |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38543 OptimizeRx Corporation (Exact name of re |
|
| April 15, 2024 |
Exhibit 10.27 March 1, 2024 Stephen Silvestro 41 Fletcher Lane Hollis, NH 03049 Dear Steve, On behalf of OptimizeRx Corporation (the “Company”), we are excited to make this amended and restated employment offer to you for the full-time, exempt position of President (this “Amended and Restatement Employment Agreement”), effective upon execution of this Amended and Restatement Employment Agreement ( |
|
| April 15, 2024 |
Exhibit 10.26 March 6, 2024 William J. Febbo 142 Calle Violeta San Juan, Puerto Rico 00927 Dear Will, On behalf of OptimizeRx Corporation (the “Company”), we are excited to make this amended and restated employment offer to you for the full-time, exempt position of Chief Executive Officer and member of the Company Board of Directors (this “Amended and Restatement Employment Agreement”), effective |
|
| April 15, 2024 |
Amended OptimizeRx Corporation Executive Severance Plan dated April 12, 2024. Exhibit 10.28 OPTIMIZERX CORPORATION EXECUTIVE SEVERANCE PLAN* Plan Document/Summary Plan Description OptimizeRx Corporation (the “Company”) has adopted this OptimizeRx Corporation Executive Severance Plan (the “Plan”) for the benefit of certain employees of the Company and its subsidiaries (hereinafter referred to as the “Company Group”), on the terms and conditions hereinafter stated, effective |
|
| April 15, 2024 |
OptimizeRx Corporation Clawback Policy Exhibit 97.1 OPTIMIZERX CORPORATION Clawback Policy The Board of Directors (the “Board”) of OptimizeRx Corporation (the “Company”) has determined that it is in the best interests of the Company to adopt this Clawback Policy (this “Policy”), which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement (as defined below). This Policy is designed to comp |
|
| April 15, 2024 |
Exhibit 21.1 OptimizeRx Corporation List of Subsidiaries ● Healthy Offers, Inc. (d/b/a Medicx Health), a Nevada corporation ● CareSpeak Communications, Inc., a New Jersey corporation ● CareSpeak Communications, d.o.o., a controlled foreign corporation incorporated in Croatia ● Cyberdiet, a controlled foreign corporation incorporated in Israel |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 28, 2024 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 2, 2024 |
Exhibit 99.1 C O R P O R A T E P A R T I C I P A N T S William J. Febbo, Chief Executive Officer Edward Stelmakh, ChiefFinancial Officer and Chief Operational Officer Steve Silvestro, President Marion Odence-Ford, General Counsel Andrew D’Silva, SVP of Corporate Finance C O N F E R E N C E C A L L P A R T I C I P A N T S Sean Dodge, RBC Capital Markets Stephanie Davis, Barclays William Wood, B. Ri |
|
| April 2, 2024 |
Reconciliation of Non-GAAP Measures OptimizeRx Corporation (preliminary unaudited) Exhibit 99.2 Reconciliation of Non-GAAP Measures (preliminary and unaudited) Reconciliation of Non-GAAP Measures OptimizeRx Corporation (preliminary unaudited) For the Three Months For the Twelve Months Ended December 31, Ended December 31, (in $ millions) 2023 2022 2023 2022 GAAP net income (loss) (7.2 ) (0.3 ) (20.6 ) (11.4 ) Depreciation and amortization 1.0 0.5 2.4 2.0 Stock-based compensation |
|
| April 2, 2024 |
Exhibit 10.1 AMENDMENT NO. 1 TO FINANCING AGREEMENT AMENDMENT NO. 1 TO FINANCING AGREEMENT, dated as of March 29, 2024 (this “Amendment”), to the Financing Agreement, dated as of October 11, 2023 (as amended, restated, supplemented or otherwise modified from time to time, including by that certain Joinder Agreement, dated as of October 24, 2023, by and among the Lead Borrower (as defined below), O |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transiti |
|
| March 11, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2024 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 11, 2024 |
Exhibit 99.1 OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023 WALTHAM, Mass. – March 11, 2024 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today provided an update |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* OptimizeRx Corporation (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 68401U204 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 13, 2024 |
OPRX / OptimizeRx Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: OptimizeRx Corp Title of Class of Securities: Common Stock CUSIP Number: 68401U204 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rul |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 24, 2024 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| January 26, 2024 |
OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape Exhibit 99.1 OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape WALTHAM, MA. – January 25, 2024– OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, is pleased to announce changes to its Board of Directors reflecting a |
|
| January 5, 2024 |
HEALTHY OFFERS, INC. FINANCIAL STATEMENTS YEARS ENDED DECEMBER 31, 2022 AND 2021 Exhibit 99.2 HEALTHY OFFERS, INC. FINANCIAL STATEMENTS YEARS ENDED DECEMBER 31, 2022 AND 2021 1 Independent Auditor’s Report 3 Balance Sheets as of December 31, 2022 and 2021; 4 Statements of Income for the years ended December 31, 2022 and 2021; 5 Statements of Changes in Stockholders’ Equity for the years ended December 31, 2022 and 2021; 6 Statements of Cash Flows for the years ended December 3 |
|
| January 5, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 20, 2023 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporatio |
|
| January 5, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.4 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Unless the context otherwise requires, the “Company” refers to OptimizeRx Corporation, a Nevada Corporation and “Medicx” refers to Healthy Offers, Inc., a Nevada corporation d/b/a Medicx Health. Description of the Business Combination On October 24, 2023, as a result of the previously announced Agreement and Plan of Merger ( |
|
| January 5, 2024 |
HEALTHY OFFERS, INC. FINANCIAL STATEMENTS THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022 Exhibit 99.3 HEALTHY OFFERS, INC. FINANCIAL STATEMENTS THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022 1 Balance Sheets as of June 30, 2023 and December 31, 2022 (unaudited); 2 Statements of Income for the three and six months ended June 30, 2023 and 2022 (unaudited); 3 Statements of Changes in Stockholders’ Equity for the three and six months ended June 30, 2023 and 2022 (unaudited); 5 Statemen |
|
| December 29, 2023 |
OPRX / OptimizeRx Corporation / Divisadero Street Capital Management, LP Passive Investment SC 13G 1 d1092387913-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* OptimizeRx Corporation (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 68401U204 (CUSIP Number) December 22, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| November 28, 2023 |
OPRX / OptimizeRx Corp / Weintraub Michael - SCHEDULE 13G Passive Investment SC 13G 1 ea189150-13gweintrauboptim.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 OptimizeRx Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 68401U204 (CUSIP Number) October 24, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2023 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| November 6, 2023 |
Exhibit 99.1 OptimizeRx Reports Third Quarter 2023 Financial Results - Increases guidance for 2023 and introduces guidance for 2024 - Total revenue of $16.3 million - GAAP net loss per share of $(0.17) - Non-GAAP net income per share of $0.09 - Total DAAP (fka RWD) deals for the year now stands at 16 - Completed acquisition of Medicx Health after quarter end WALTHAM, Mass. – November 6, 2023 – Opt |
|
| October 25, 2023 |
Exhibit 99.1 OptimizeRx Announces Completion of Medicx Acquisition and Sets Third Quarter 2023 Conference Call for November 6, 2023, at 8:30 a.m. ET Executive Leadership expands with Steve Silvestro being promoted to President, and Theresa Greco assuming the role of Chief Commercial Officer WALTHAM, Ma. – October 25, 2023 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of h |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 20, 2023 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| October 25, 2023 |
Exhibit 10.1 CONFIDENTIAL COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (this “Agreement”) is made and entered into as of this day of , 2023, by and among OptimizeRx Corporation, a Nevada corporation (the “Company”), and the individuals listed on Exhibit A hereto (the “Purchasers”). Background A. The Company is a party to that certain Agreement and Plan of Merger (the “Merge |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 11, 2023 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| October 16, 2023 |
OPTIMIZERX CORPORATION RECONCILIATION of GAAP to NON-GAAP FINANCIAL MEASURES Exhibit 99.1 OptimizeRx Announces Agreement to Acquire Medicx Health for $95 million to Expand its Omnichannel Reach to Consumers Preannounces Preliminary Third Quarter 2023 Results OptimizeRx adds new, proven, profitable technologies to become the most comprehensive healthcare marketing platform in the nation. Consolidated revenue run rate will increase to nearly $100 million and the acquisition |
|
| October 16, 2023 |
Exhibit 10.2 JOINDER AND SUPPORT AGREEMENT TO AGREEMENT AND PLAN OF MERGER The undersigned (the “Undersigned”) is executing and delivering this Joinder and Support Agreement (this “Joinder”), dated as of the date set forth below, to the Agreement and Plan of Merger, dated as of October 11, 2023 (as the same has been or may hereafter be amended, amended and restated, supplemented, or otherwise modi |
|
| October 16, 2023 |
Exhibit 10.4 Execution Version Blue Torch Finance, LLC c/o Blue Torch Capital LP 150 East 58th Street, 39th Floor New York, NY 10155 CONFIDENTIAL October 11, 2023 OptimizeRx Corporation 260 Charles Street, Suite 302 Waltham, MA 02453 Attention: Edward Stelmakh, Chief Financial Officer Fee Letter Ladies and Gentlemen: Reference is made to that certain Financing Agreement, dated as of October 11, 20 |
|
| October 16, 2023 |
Exhibit 10.3 Execution Version FINANCING AGREEMENT Dated as of October 11, 2023 by and among OPTIMIZERX CORPORATION, as the Lead Borrower, THE LENDERS FROM TIME TO TIME PARTY HERETO, as Lenders, and BLUE TORCH FINANCE, LLC, as Administrative Agent and Collateral Agent FOR PURPOSES OF SECTIONS 1272, 1273 AND 1275 OF THE INTERNAL REVENUE CODE, THE TERM LOANS ARE BEING ISSUED WITH ORIGINAL ISSUE DISC |
|
| October 16, 2023 |
Exhibit 10.1 AGREEMENT AND PLAN OF MERGER by and among OPTIMIZERX CORPORATION, HEALTHY OFFERS, INC., THE SECURITYHOLDERS OF HEALTHY OFFERS, INC., and MICHAEL WEINTRAUB, as Securityholder Representative Dated as of October 11, 2023 TABLE OF CONTENTS Page 1. The Merger 1 1.1. Merger 1 1.2. The Effective Time 1 1.3. Effect of the Merger 2 1.4. Articles of Incorporation 2 1.5. Bylaws 2 1.6. Directors |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 14, 2023 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 14, 2023 |
Exhibit 99.1 OptimizeRx Reports Second Quarter 2023 Financial Results - RWD.AI-enabled portion of the core business sees 186% YOY growth during the first half of 2023 - Non-core business is lagging - Total revenue of $13.8 million - GAAP net loss per share of $(0.24) - Non-GAAP net loss per share of $(0.01) ROCHESTER, Mich. – August 14, 2023 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a lea |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* OptimizeRx Corporation (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 68401U204 (CUSIP Number) May 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| May 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2023 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 10, 2023 |
Exhibit 99.1 OptimizeRx Reports First Quarter 2023 Financial Results - Total revenue of $13.0 million - GAAP net loss per share of $(0.37) - Non-GAAP net loss per share of $(0.09) ROCHESTER, Mich. – May 10, 2023 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the three month |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 14, 2023 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A Amendment No. |
|
| March 10, 2023 |
Exhibit 21.1 List of Subsidiaries OptimizeRx Corporation, A Michigan corporation CareSpeak Communications, Inc., a New Jersey corporation CareSpeak Communications D.O.O., a controlled foreign corporation located in Croatia. Cyberdiet, a controlled foreign corporation located in Israel |
|
| March 10, 2023 |
OptimizeRx Corporation Executive Severance Plan Exhibit 10.18 OPTIMIZERX CORPORATION EXECUTIVE SEVERANCE PLAN Plan Document/Summary Plan Description OptimizeRx Corporation (the “Company”) has adopted this OptimizeRx Corporation Executive Severance Plan (the “Plan”) for the benefit of certain employees of the Company and its subsidiaries (hereinafter referred to as the “Company Group”), on the terms and conditions hereinafter stated, effective a |
|
| March 10, 2023 |
EX-3.3 2 f10k2022ex3-3optimizerx.htm THIRD AMENDED AND RESTATED BYLAWS OF THE COMPANY Exhibit 3.3 THIRD AMENDED AND RESTATED BYLAWS OF OPTIMIZERX CORPORATION (A NEVADA CORPORATION) ARTICLE I OFFICES Section 1.1 Principal Office. The principal office of OptimizeRx Corporation (the “Corporation”) shall be at such place within or outside of the State of Nevada as the board of directors of the Corpora |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A Amendment No. |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38543 OptimizeRx Corporation |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38543 OptimizeRx Corporation (Exact name of re |
|
| March 10, 2023 |
Fourth Addendum to the Employment Agreement with William J. Febbo Exhibit 10.19 March 8, 2023 Mr. William Febbo Re: Fourth Addendum to the Offer Letter, dated February 25, 2019, as amended, by and between William Febbo and OptimizeRx Corporation Dear Will, On behalf of OptimizeRx Corporation (the “Company”), we are delighted to provide you with this letter agreement (this “Fourth Addendum”), effective as of March 8, 2023 (the “Effective Date”), which will update |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A Amendment No. |
|
| March 8, 2023 |
OptimizeRx Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 OptimizeRx Reports Fourth Quarter and Full Year 2022 Financial Results - Q4 revenue of $19.7 million, down 3% year-over-year and up 30% quarter-over-quarter - Q4 gross profit increased 1% year-over-year to $12.5 million as gross margins increased from 61% to 63% - Generated $10.7 million in cash flow from operations in 2022 - Repurchased 1.2 million shares during 2022 at an average pr |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 8, 2023 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 9, 2023 |
OPRX / OptimizeRx Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: OptimizeRx Corp. Title of Class of Securities: Common Stock CUSIP Number: 68401U204 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru |
|
| November 8, 2022 |
OptimizeRx Reports Third Quarter 2022 Financial Results Exhibit 99.1 OptimizeRx Reports Third Quarter 2022 Financial Results - Q3 Revenue of $15.1 million, down 6% year-over-year and up 8% quarter-over-quarter - Gross profit increased 4% year-over-year to $9.4 million as gross margins increased from 56% to 62% - Generated $7.9 million in cash flow from operations during the first nine months of 2022 - Repurchased 1.1 million shares - year to date - at |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 8, 2022 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 ? Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| August 10, 2022 |
Exhibit 99.1 OptimizeRx Reports Second Quarter 2022 Financial Results, Innovative Platform Expansions Now Extends Reach to HCPs Across Social Media and Patients at Point-of-Dispense - Revenue Up 3% to $14.0 million, driven by new customer and program launches - Increase in breadth and scope of brand deal size represents further momentum in the validation of our value proposition - Generated $4.4 m |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2022 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| August 9, 2022 |
Exhibit 99.1 OptimizeRx Reports Second Quarter 2022 Financial Results, Innovative Platform Expansions Now Extends Reach to HCPs Across Social Media and Patients at Point-of-Dispense - Revenue Up 3% to $14.0 million, driven by new customer and program launches - Increase in breadth and scope of brand deal size represents further momentum in the validation of our value proposition - Generated $4.4 m |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2022 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ? Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| June 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction (Commission File Number) (IRS Emplo |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 17, 2022 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 ? Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2022 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 4, 2022 |
Exhibit 99.1 OptimizeRx Reports First Quarter 2022 Financial Results, Revenue Up 22%, Successfully Completes EvinceMed Acquisition - Revenue Up 22% to $13.7 million on increased average revenue per top 20 pharmaceutical manufacturer client - Traction with top 20 pharmaceutical manufacturers continues to advance and drive growth - Cash flow positive from operations of $4.1 million ROCHESTER, Mich. |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? D |
|
| March 17, 2022 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2022 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 4, 2022 |
Exhibit 10.3 Amendment to Employment Agreement This first amendment (this ?Amendment?) to the Employment Agreement, dated January 29, 2021, is made this 28th day of February 2022, by and between OptimizeRx Corporation, a Nevada corporation (the ?Company?), and Marion Odence-Ford (the ?Executive?). Base Salary: The Executive shall be entitled to receive a base salary at a rate of $296,000.00 per an |
|
| March 4, 2022 |
Exhibit 10.1 OPTIMIZERX CORPORATION 2022 CASH BONUS PLAN 1. BACKGROUND AND PURPOSE OptimizeRx Corporation, a Nevada corporation, hereby adopts the 2022 Cash Bonus Plan (the ?Plan?), effective as provided in Paragraph 10. The purpose of the Plan is to align officers? and other employees? efforts with the strategic goals of the Company through competitive annual incentive opportunities. 2. DEFINITIO |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 28, 2022 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| March 4, 2022 |
Exhibit 10.2 Second Amendment to Employment Agreement This second amendment (this ?Second Amendment?) to the Employment Agreement, dated March 18, 2019, as amended March 10, 2020 (the ?Agreement?), is made this 28th day of February 2022, by and between OptimizeRx Corporation, a Nevada corporation (the ?Company?), and Stephen Silvestro (the ?Executive?). Base Salary: The Executive shall be entitled |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38543 OptimizeRx Corporation (Exact name of re |
|
| February 28, 2022 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ?OptimizeRx Corporation has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $.001 per share (the ?common stock?). References herein to ?we,? ?us? and ?our company? refer to OptimizeRx Corp |
|
| February 28, 2022 |
Exhibit 21.1 List of Subsidiaries OptimizeRx Corporation, A Michigan corporation CareSpeak Communications, Inc., a New Jersey corporation CareSpeak Communications D.O.O., a controlled foreign corporation located in Croatia. RMDY Health, Inc., A Delaware corporation Cyberdiet, a controlled foreign corporation located in Israel |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 24, 2022 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| February 24, 2022 |
Exhibit 99.1 OptimizeRx Reports Fourth Quarter and Full Year 2021 Financial Results, Revenue Increased 42%, Demand from Large Pharma Gains Momentum - Fourth quarter revenue Up 24% to $20.3 million, gross profit margin of 61% - Introduction of key performance indicators (KPIs) representing ?land and expand? strategy with key customer accounts - Cash flow positive from operations of $0.7 million in |
|
| February 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 15, 2022 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| February 15, 2022 |
Exhibit 99.1 OptimizeRx Announces Preliminary Fourth Quarter 2021 Financial Results, Introduces New Key Performance Indicators and Provides Initial 2022 Guidance ROCHESTER, Mich. ? February 15, 2022 ? OptimizeRx Corp. (the ?Company?) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced preliminary unaudited financial a |
|
| February 11, 2022 |
OPRX / OptimizeRx Corporation / BLAIR WILLIAM & CO/IL - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* OptimizeRx Corp (Name of Issuer) Common Stock (Title of Class of Securities) 68401U204 (CUSIP Number) December 31, 2021 (Date of Event Whic |
|
| February 10, 2022 |
OPRX / OptimizeRx Corporation / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: OptimizeRx Corp. Title of Class of Securities: Common Stock CUSIP Number: 68401U204 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 1 |
|
| December 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 21, 2021 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| December 22, 2021 |
Exhibit 10.1 December 21, 2021 Miriam Paramore Dear Miriam, On behalf of OptimizeRx Corporation (the ?Company?), we want to congratulate you on your upcoming retirement and thank you for your service as President & Chief Strategy Officer! With a target retirement date of December 31, 2021 (?Retirement Date?), your Offer of Employment, dated July 17, 2017, as amended on September 10, 2018 and Febru |
|
| December 22, 2021 |
Exhibit 99.1 OptimizeRx CEO Issues Open Letter to Shareholders Detailing the Completion of Internal Management Changes ROCHESTER, Mich. ? December 22, 2021 ? OptimizeRx Corp. (the ?Company?) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today issued an open letter from the CEO to shareholders detailing the completion of interna |
|
| November 15, 2021 |
EX-99.1 2 ea150503ex99-1optimizerx.htm TRANSCRIPT OF OPTIMIZERX CORPORATION CONFERENCE CALL ON NOVEMBER 9, 2021 Exhibit 99.1 CORPORATE PARTICIPANTS William Febbo, Chief Executive Officer, Director Edward Stelmakh, Chief Financial Officer and Chief Operations Officer Stephen Silvestro, Chief Commercial Officer Andrew D’Silva, Senior Vice President of Corporate Finance CONFERENCE CALL PARTICIPANTS J |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2021 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction (Commission File Number) (IRS Emplo |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2021 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| November 10, 2021 |
Exhibit 99.1 OptimizeRx Reports Third Quarter 2021 Financial Results, Revenue Increased 53% in Continued Scale Up for Accelerated Growth - Revenue Up 53% to $16.1 million, closing on 11 enterprise contracts - Brands adopting OptimizeRx solutions increases to 182 from 140 in the past 6 months - Real-world evidence (?RWE?) continues to gain traction and build revenue generating momentum - Cash flow |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 or ? Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| October 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 15, 2021 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| October 19, 2021 |
Exhibit 10.1 September 22, 2021 William Febbo Re: Third Addendum to the Offer Letter, dated February 25, 2019, as amended, by and between William Febbo and OptimizeRx Corporation Dear Will, On behalf of OptimizeRx Corporation (the ?Company?), we are delighted to provide you with this letter agreement (this ?Third Addendum?), effective as of September 22, 2021 (the ?Agreement Date?) which will upda |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 24, 2021 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 30, 2021 |
Exhibit 99.1 OptimizeRx Appoints Seasoned Financial and Operational Executive, Edward Stelmakh as Chief Financial Officer and Chief Operations Officer Doug Baker transitions to executive vice president of finance and accounting ROCHESTER, Mich. ? September 30, 2021 ? OptimizeRx Corp. (the ?Company?) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and |
|
| September 30, 2021 |
Exhibit 10.1 September 20, 2021 Edward Stelmakh Dear Ed, On behalf of OptimizeRx Corporation (the ?Company?), we are excited to extend an offer to join us full-time in the exempt position of Chief Financial Officer / Chief Operations Officer with an anticipated start date of October 11, 2021 (?Start Date?). The terms of our offer are outlined below and are subject to a standard background check an |
|
| September 29, 2021 |
Exhibit 99.1 OptimizeRx Survey Demonstrates Value of Digital Solutions in Addressing Unmet Patient and Provider Needs in Diabetes - Digital solutions provide new opportunities to support brand and HCP patient engagement challenges in survey of top U.S. endocrinologists ROCHESTER, Mich. ? September 29, 2021 ? OptimizeRx Corp. (the ?Company?) (Nasdaq: OPRX), a leading provider of point-of-care techn |
|
| September 29, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| September 14, 2021 |
Other Events, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 14, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| September 14, 2021 |
Exhibit 99.1 OptimizeRx Announces Significant Platform Enhancement to Digitize Pharmaceutical Access Solutions Launch of digital solution supports major industry paradigm shift towards improving patient care and adherence through technology ROCHESTER, Mich. ? September 14, 2021 ? OptimizeRx Corp. (the ?Company?) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patie |
|
| September 8, 2021 |
Other Events, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 8, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| September 8, 2021 |
Exhibit 99.1 OptimizeRx Welcomes Andrew D?Silva as Senior Vice President of Corporate Finance D?Silva Brings Over 10 Years of Equity Research Experience ROCHESTER, Mich. ? September 08, 2021 ? OptimizeRx Corp. (the ?Company?) (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has appointed Andrew D?Silva to the new position of senior |
|
| September 7, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 7, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| September 7, 2021 |
Exhibit 99.1 OptimizeRx Recognized as a Finalist in Questex?s Fierce Pharma Marketing Awards 2021 OptimizeRx Recognized in the COVID-19 Pandemic-Related Campaign Category ROCHESTER, Mich. ? September 7, 2021 ? OptimizeRx Corp. (the ?Company?) (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, announced today that it has been selected |
|
| September 1, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 1, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| September 1, 2021 |
OptimizeRx to Present at Upcoming September Investor Conferences Exhibit 99.1 OptimizeRx to Present at Upcoming September Investor Conferences ROCHESTER, Mich. ? September 1, 2021 ? OptimizeRx Corp. (the ?Company?) (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, announced today that Will Febbo, OptimizeRx?s CEO will present at the upcoming Lake Street Capital Markets, ?The Best Ideas Growth (BI |
|
| August 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 31, 2021 |
As filed with the Securities and Exchange Commission on August 31, 2021 As filed with the Securities and Exchange Commission on August 31, 2021 Registration No. |
|
| August 31, 2021 |
As filed with the Securities and Exchange Commission on August 31, 2021 As filed with the Securities and Exchange Commission on August 31, 2021 Commission File No. |
|
| August 25, 2021 |
Exhibit 10.1 OPTIMIZERX CORPORATION 2021 EQUITY INCENTIVE PLAN SECTION 1. Purpose; Definitions The purpose of this Plan is to provide for Eligible Individuals of the Company and its Affiliates an equity-based incentive to maintain and enhance the performance and profitability of the Company. For purposes of this Plan, the following terms are defined as set forth below: ?Affiliate? means any entity |
|
| August 25, 2021 |
Exhibit 10.5 OptimizeRx Corporation 2021 Equity Incentive Plan Notice of Restricted Stock Unit Grant You (the ?Grantee?) have been granted the following award of Restricted Stock Units (?Restricted Stock Units? or ?RSUs?) with respect to shares of OptimizeRx Corporation (the ?Company?) common stock, par value $0.001 per share (the ?Shares?), pursuant to the OptimizeRx Corporation 2021 Equity Incen |
|
| August 25, 2021 |
EXHIBIT 10.4 OptimizeRx Corporation 2021 Equity Incentive Plan Notice of Restricted Stock Unit Grant You (the ?Grantee?) have been granted the following award of Restricted Stock Units (?Restricted Stock Units? or ?RSUs?) with respect to shares of OptimizeRx Corporation (the ?Company?) common stock, par value $0.001 per share (the ?Shares?), pursuant to the OptimizeRx Corporation 2021 Equity Incen |
|
| August 25, 2021 |
Exhibit 10.3 OptimizeRx Corporation 2021 Equity Incentive Plan Notice of Stock Option Grant You (the ?Optionee?) have been granted the following option (the ?Option?) to purchase Common Stock of OptimizeRx Corporation (the ?Company?), par value $0.001 per share (?Share?), pursuant to the OptimizeRx Corporation 2021 Equity Incentive Plan (the ?Plan?): Name of Optionee: [Name] Total Number of Shares |
|
| August 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction (Commission File Number) (IRS Em |
|
| August 25, 2021 |
Exhibit 10.2 OptimizeRx Corporation 2021 Equity Incentive Plan Notice of Stock Option Grant You (the ?Optionee?) have been granted the following option (the ?Option?) to purchase Common Stock of OptimizeRx Corporation (the ?Company?), par value $0.001 per share (?Share?), pursuant to the OptimizeRx Corporation 2021 Equity Incentive Plan (the ?Plan?): Name of Optionee: [Name] Total Number of Shares |
|
| August 17, 2021 |
Exhibit 99.1 OptimizeRx and Demandbase Form Exclusive Account-Based-Experience (ABX) Partnership ? Delivering Industry?s Most Powerful ABX Solution for Life Sciences The Companies? combined point-of-care-engine creates an unmatched network of direct-to-physician digital interaction ROCHESTER, Mich. ? August 17, 2021 ? OptimizeRx Corp. (the ?Company?) (Nasdaq: OPRX), a leading provider of digital h |
|
| August 17, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 17, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I. |
|
| August 11, 2021 |
EX-99.1 2 ea145559ex99-1optimizerx.htm CONFERENCE CALL TRANSCRIPT Exhibit 99.1 C O R P O R A T E P A R T I C I P A N T S William Febbo, Chief Executive Officer, Director Douglas Baker, Chief Financial Officer Stephen Silvestro, Chief Commercial Officer C O N F E R E N C E C A L L P A R T I C I P A N T S Ryan Daniels, William Blair Sean Dodge, RBC Andrew D’Silva, B. Riley Securities Eric Martinuzzi |
|
| August 11, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I. |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I.R |
|
| August 5, 2021 |
Exhibit 99.1 OptimizeRx Reports Second Quarter 2021 Financial Results, Revenue Up 55% as Leading Pharma Brands Aggressively Seek Improved ROI Through Technology Adoption - Revenue Up 55% to $13.6 million, closing on 19 enterprise contracts - Enterprise deals pipeline grows from 46 to 63 - Brands adopting OptimizeRx solutions increases to 140 from 80 in the past 6 months - Successful implementation |
|
| August 4, 2021 |
Exhibit 10.1 Employment Agreement Addendum 2 Addendum to agreement dated February 25, 2019 This second addendum to the employment agreement (the ?Addendum?) is made this 24th day of September 2020, by and between OptimizeRx, Corporation (the ?Company?), a Nevada Company, and William Febbo (the ?Executive?). Severance The following paragraph is hereby deleted in its entirety and replaced as indicat |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 ? Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| July 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Emp |
|
| July 27, 2021 |
OptimizeRx Sets Second Quarter Fiscal 2021 Conference Call for Wednesday, August 4 at 4:30 p.m. ET Exhibit 99.1 OptimizeRx Sets Second Quarter Fiscal 2021 Conference Call for Wednesday, August 4 at 4:30 p.m. ET ROCHESTER, Mich. ? July 27, 2021 ? OptimizeRx Corp. (the ?Company?) (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will hold a conference call on Wednesday, August 4, 2021, at 4:30 p.m. Eastern time to discuss its resul |
|
| July 14, 2021 |
Exhibit 99.1 OptimizeRx Announces Agreement with a Top Pharmaceutical Manufacturer to Use its Evidence-Based Physician Engagement to Solve Lapse in Medical Coverage Barrier for Patients OptimizeRx?s AI-driven platform leverages real-world evidence (RWE) to support doctors in their efforts to maintain patient treatment plans ROCHESTER, Mich. ? July 14, 2021 ? OptimizeRx Corp. (the ?Company?) (Nasda |
|
| July 14, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 14, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I.R. |
|
| July 8, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| June 25, 2021 |
Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF OPTIMIZERX CORPORATION (A NEVADA CORPORATION) ARTICLE I OFFICES Section 1.1 Principal Office. The principal office of OptimizeRx Corporation (the ?Corporation?) shall be at such place within or outside of the State of Nevada as the board of directors of the Corporation (the ?Board?) shall from time to time designate. Section 1.2 Other Offices. The |
|
| June 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File |
|
| June 25, 2021 |
Exhibit 14.1 OPTIMIZERX CORPORATION Code of Business Conduct and Ethics INTRODUCTION This Code of Business Conduct and Ethics (this ?Code?) contains general guidelines for conducting the business of OptimizeRx Corporation and its subsidiaries (collectively, the ?Company? or ?OptimizeRx?) and applies to all of the Company?s directors, officers and employees. We refer to all officers and other emplo |
|
| June 15, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I.R. |
|
| June 15, 2021 |
EX-99.1 2 ea142752ex99-1optimizerx.htm PRESS RELEASE, DATED JUNE 15, 2021 Exhibit 99.1 OptimizeRx Aligned With Pharma Across Fast Growing Specialty Therapeutic Areas -Continued focus on building and closing pipeline of enterprise solutions across oncology, cardiology and immunology ROCHESTER, Mich. – June 15, 2021 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of digital hea |
|
| June 2, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S |
|
| June 2, 2021 |
OptimizeRx Named to LD Micro’s “Hall of Fame” As One of the Top 50 Performing Companies Exhibit 99.1 OptimizeRx Named to LD Micro?s ?Hall of Fame? As One of the Top 50 Performing Companies ROCHESTER, Mich. ? June 1, 2021 ? OptimizeRx Corp. (the ?Company?) (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, announced today that Will Febbo, OptimizeRx?s CEO will participate in the LD Micro Virtual Invitational (XI) confere |
|
| May 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 26, 2021 OptimizeRx Corporation (Exact name of registrant as specified in charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 25, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 25, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Empl |
|
| May 25, 2021 |
OptimizeRx to Participate in the William Blair 41st Annual Growth Stock Conference Exhibit 99.1 OptimizeRx to Participate in the William Blair 41st Annual Growth Stock Conference ROCHESTER, Mich. ? May 25, 2021 ? OptimizeRx Corp. (the ?Company?) (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, announced today that Will Febbo, OptimizeRx?s, CEO will participate in a fireside chat at the William Blair 41st Annual G |
|
| May 11, 2021 |
OptimizeRx to Present at RBC Capital Markets Global Virtual Healthcare Conference on May 19, 2021 Exhibit 99.2 OptimizeRx to Present at RBC Capital Markets Global Virtual Healthcare Conference on May 19, 2021 ROCHESTER, Mich. ? May 11, 2021 ? OptimizeRx Corp. (the ?Company?) (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will participate in RBC Capital Markets Global Healthcare Virtual Conference. Will Febbo, OptimizeRx?s CEO |
|
| May 11, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. |
|
| May 11, 2021 |
C O R P O R A T E P A R T I C I P A N T S EX-99.1 2 ea140661ex99-1optimizerx.htm CONFERENCE CALL TRANSCRIPT DATED MAY 6, 2021 Exhibit 99.1 C O R P O R A T E P A R T I C I P A N T S William Febbo, Chief Executive Officer, Director Douglas Baker, Chief Financial Officer Stephen Silvestro, Chief Commercial Officer Miriam Paramore, President C O N F E R E N C E C A L L P A R T I C I P A N T S Ryan Daniels, William Blair Andrew D’Silva, B. Ril |
|
| May 7, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. |
|
| May 7, 2021 |
Exhibit 99.1 OptimizeRx Reports First Quarter 2021 Financial Results, Revenue Up 48% on Rising Enterprise Adoption of Digital Health - Revenue Up 48% to $11.2 million, closing on 33 enterprise contracts - Expanded recurring revenue stream, reaching new base of customers - Cash flow positive from operations of $1.7 million ROCHESTER, Mich. ? May 6, 2021 ? OptimizeRx Corp. (the ?Company?) (Nasdaq: O |
|
| May 7, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. |
|
| May 6, 2021 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 ? Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| April 28, 2021 |
Exhibit 99.1 OptimizeRx Expands Omni-channel Platform Reach at Point-Of-Care Several New Partnerships Expand Reach to Over 50% of Oncologists in the U.S. and Unlock Novel Touchpoints for Life Sciences to Engage Physicians ROCHESTER, Mich. ? April 27, 2021 ? OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has annou |
|
| April 28, 2021 |
OptimizeRx Sets First Quarter 2021 Conference Call for Thursday, May 6, 2021 at 4:30 p.m. ET Exhibit 99.2 OptimizeRx Sets First Quarter 2021 Conference Call for Thursday, May 6, 2021 at 4:30 p.m. ET ROCHESTER, Mich. ? April 28, 2021 ? OptimizeRx Corporation (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will hold a conference call on Thursday, May 6, 2021, at 4:30 p.m. Eastern time to discuss its results for the first qu |
|
| April 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 27, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I.R |
|
| April 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* OPTIMIZERX CORPORATION (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 68401U105 (CUSIP Number) Shawn Turner Holland & Knight LLP 1801 California Street, Suite 5000 Denver, Colorado 80202 (303) 974-6660 (Name, Add |
|
| April 13, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 13, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I.R |
|
| April 13, 2021 |
Exhibit 99.1 OptimizeRx Named to Financial Times ?The Americas? Fastest-Growing Companies List for the Second Consecutive Year Ranked #277, highlighting the growth potential and convergence between technology and healthcare ROCHESTER, Mich. ? April 13, 2021 ? OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians, and patients, has re |
|
| March 29, 2021 |
Fifth Amended and Restated 2013 Equity Incentive Plan Exhibit 4.4 OptimizeRx Corp. (the ?Company?) FIFTH AMENDED AND RESTATED 2013 INCENTIVE PLAN Section 1. PURPOSE The purpose of the Fifth Amended and Restated OptimizeRx Corp. 2013 Incentive Plan (the ?Plan?) is to attract, retain and motivate employees, officers, directors, consultants, agents, advisors and independent contractors of the Company and its Related Companies by providing them the oppor |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OptimizeRx Corp. (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 400 Water Street, Suite 200, Rochester, MI 48307 (Address of Principal Ex |
|
| March 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* OptimizeRx Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 68401U105 (CUSIP Number) February 15, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| March 16, 2021 |
OptimizeRx Recurring Revenue Grows as it Secures 19 New Enterprise-Level Engagements in Q1 2021 Exhibit 99.1 OptimizeRx Recurring Revenue Grows as it Secures 19 New Enterprise-Level Engagements in Q1 2021 ROCHESTER, Mich. – March 16, 2021 – OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has secured 19 new enterprise-level deals for 2021 that provide access to the company’s full suite of solutions and nation |
|
| March 16, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I.R |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38543 OptimizeRx Corporation (Exact name of re |
|
| March 8, 2021 |
Exhibit 21.1 List of Subsidiaries OptimizeRx Corporation, A Michigan corporation CareSpeak Communications, Inc., a New Jersey corporation CareSpeak Communications D.O.O., a controlled foreign corporation located in Croatia. RMDY Health, Inc., A Delaware corporation Cyberdiet, a controlled foreign corporation located in Israel |
|
| March 4, 2021 |
Other Events, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 3, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I.R. |
|
| March 4, 2021 |
OptimizeRx to Participate at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021 Exhibit 99.1 OptimizeRx to Participate at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021 ROCHESTER, Mich. – March 3, 2021 – OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has been invited to present at the 33rd Annual ROTH Growth Conference being held virtually on March 15-17, 2021. The conference w |
|
| February 26, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| February 26, 2021 |
OptimizeRX Corporation Fourth Quarter and Full Year 2020 Conference Call February 24, 2021 Exhibit 99.1 OptimizeRX Corporation Fourth Quarter and Full Year 2020 Conference Call February 24, 2021 OptimizeRX Corporation - Fourth Quarter and Full Year 2020 Conference Call, February 24, 2021 C O R P O R A T E P A R T I C I P A N T S William Febbo, Chief Executive Officer Douglas Baker, Chief Financial Officer Steve Silvestro, Chief Commercial Officer Miriam Paramore, President and Chief Str |
|
| February 25, 2021 |
Exhibit 99.1 OptimizeRx Reports Q4 2020 Revenue Up 123% to Record $16.4 Million, Driving Net Income of $1.4 Million or $0.08 Per Share ROCHESTER, Mich. ? February 24, 2021 ? OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, reported results for the fourth quarter and full year ended December 31, 2020. Quarterly and |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 25, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| February 23, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| February 23, 2021 |
Exhibit 99.1 OptimizeRx?s Angelo Campano Named to MM+M 40 Under 40 List List Celebrates Accomplished Young Talent in Medical Marketing ROCHESTER, Mich. ? February 23, 2021 ? OptimizeRx Corporation (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, announced its senior vice president and principal of agency channels, Angelo Campano, h |
|
| February 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* OPTIMIZERX CORPORATION (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 68401U105 (CUSIP Number) Shawn Turner Holland & Knight LLP 1801 California Street, Suite 5000 Denver, Colorado 80202 (303) 974-6660 (Name, Add |
|
| February 18, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 18, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| February 18, 2021 |
Exhibit 99.1 OptimizeRx Sets Fourth Quarter and Full Year 2020 Conference Call for Wednesday, February 24, 2021 at 4:30 p.m. ET ROCHESTER, Mich. – February 18, 2021 – OptimizeRx Corporation (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will hold a conference call on Wednesday, February 24, 2021 at 4:30 p.m. Eastern time to discu |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* OPTIMIZERX Corporation (Name of Issuer) Common Stock, PAR VALUE $0.001 per share (Title of Class of Securities) 68401U204 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 16, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 16, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| February 16, 2021 |
Exhibit 99.1 OptimizeRx to Present at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021 ROCHESTER, Mich., February 16, 2021 – OptimizeRx Corporation (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has been invited to present at the SVB Leerink 10th Annual Global Healthcare Conference being held virtuall |
|
| February 11, 2021 |
Exhibit 10.1 January 29, 2021 Marion Odence-Ford 101 Larchwood Dr Cambridge, MA 02138 Dear: Ms. Odence-Ford On behalf of OptimizeRx Corporation (the “Company”), we are excited to extend an offer to join us full-time in the exempt position of General Counsel & Chief Compliance Officer with an anticipated start date of date of February 8, 2021. The terms of our offer are outlined below and are subje |
|
| February 11, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 001-38543 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* OptimizeRx Corp (Name of Issuer) Common Stock (Title of Class of Securities) 68401U204 (CUSIP Number) 12/31/2020 (Date of Event Which Requir |
|
| February 10, 2021 |
Underwriting Agreement dated February 9, 2021 Exhibit 1.1 1,325,000 Shares OptimizeRx Corporation Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT February 9, 2021 William Blair & Company, L.L.C. RBC CAPITAL MARKETS, LLC As Representatives of the several Underwriters named in Schedule I hereto c/o William Blair & Company, L.L.C. 150 North Riverside Plaza Chicago, Illinois 60606 RBC Capital Markets, LLC 200 Vesey Street, 10th Fl |
|
| February 10, 2021 |
Calculation of Registration Fee Filed Pursuant to Rule 424(b)(5) Registration No.: 333-252844 Calculation of Registration Fee Title of Each Class of Securities To Be Registered Amount To Be Registered (1) Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee (2) Common Stock, $0.001 par value per share 1,523,750 $49.50 $75,425,625 $8,229 (1) Includes 198,750 shares of common stock |
|
| February 10, 2021 |
Financial Statements and Exhibits, Other Events - FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2021 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 000-53605 26-1265381 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| February 10, 2021 |
OptimizeRx Announces Proposed Public Offering of Common Stock Exhibit 99.1 OptimizeRx Announces Proposed Public Offering of Common Stock ROCHESTER, Mich., February 8, 2021 – OptimizeRx Corporation (Nasdaq: OPRX) (“OptimizeRx”), a leading provider of digital health solutions for life science companies, physicians and patients, today announced it has commenced an underwritten public offering of shares of its common stock. OptimizeRx is expected to grant the un |
|
| February 10, 2021 |
OptimizeRx Announces Pricing of Public Offering of Common Stock Exhibit 99.2 OptimizeRx Announces Pricing of Public Offering of Common Stock ROCHESTER, Mich., February 9, 2021 – OptimizeRx Corporation (Nasdaq: OPRX) (“OptimizeRx”), a leading provider of digital health solutions for life science companies, physicians and patients, today announced the pricing of the previously announced underwritten public offering of 1,325,000 shares of its common stock at a pr |
|
| February 8, 2021 |
As filed with the Securities and Exchange Commission on February 8, 2021 Registration No. |
|
| February 8, 2021 |
Exhibit 4.2 OPTIMIZERX CORPORATION TO [NAME OF TRUSTEE] Trustee Indenture Dated as of , 20 Subordinated Debt Securities Table of Contents Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 SECTION 101 Definitions 2 SECTION 102 Compliance Certificates and Opinions 12 SECTION 103 Form of Documents Delivered to Trustee 12 SECTION 104 Acts of Holders 14 SECTION 105 Notices, etc., |
|
| February 8, 2021 |
SUBJECT TO COMPLETION, DATED FEBRUARY 8, 2021 Filed Pursuant to Rule 424(b)(5) Registration No.: 333-252844 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities and we are not soliciting an offer to buy t |
|
| February 8, 2021 |
Exhibit 4.1 OPTIMIZERX CORPORATION TO [NAME OF TRUSTEE] Trustee Indenture Dated as of , 20 Senior Debt Securities Table of Contents Page ARTICLE 1. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 101. Definitions 1 SECTION 102. Compliance Certificates and Opinions 9 SECTION 103. Form of Documents Delivered to Trustee 10 SECTION 104. Acts of Holders 10 SECTION 105. Notices, etc., |
